An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer

Annals of Surgery

Volumn 255, Issue 4, 2012, Pages 720-730

  Ma, Yanlei ^a   Zhang, Peng ^a   Wang, Feng ^a   Liu, Weijie ^b   Yang, Jianjun ^b   Qin, Huanlong ^a  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; BIOLOGICAL MARKER; DEOXYGLUCOSE; GLYCINE; MICROTUBULE ACTIN CROSS LINKING FACTOR 1; ONCOFETAL ANTIGEN; PROTEIN A2M; PROTEIN APOH; PROTEIN VDB; RIBITOL; THREONINE; UNCLASSIFIED DRUG; VALINE;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; GAS CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; VALIDATION PROCESS;

ADULT; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FETAL BLOOD; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; METABOLOMICS; NEURAL NETWORKS (COMPUTER); PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 84862798465     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31824a9a8b     Document Type: Article

References (59)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Sung JJY, Lau JY, Goh KL, et al. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6:871-876. (Pubitemid 41614799)
3. Jemal A,Murray T,Ward E, et al. Cancer statistics, 2005. Ca-a Cancer J Clin. 2005;55:10-30. (Pubitemid 40310185)
4. Woolf SH. The best screening test for colorectal cancer: a personal choice. N Engl J Med. 2000;343:1641-1643. (Pubitemid 32162991)
5. Walsh JME, Terdiman JP. Colorectal cancer screening: scientific review. JAMA. 2003;289:1288-1296. (Pubitemid 37432910)
6. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003; 124:544-560. (Pubitemid 36169269)
7. Celis JE, Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell. 2003;3:9-15. (Pubitemid 37448548)
8. Nedelkov D, Kiernan UA, Niederkofler EE, et al. Population proteomics: the concept, attributes, and potential for cancer biomarker research. Molecul Cellul Proteom. 2006;5:1811-1818. (Pubitemid 44688190)
9. Tyers M, Mann M. From genomics to proteomics. Nature. 2003;422:193-197. (Pubitemid 36362756)
10. Abate-Shen C, Shen MM. DIAGNOSTICS The prostate-cancer metabolome. Nature. 2009;457:799-800.
11. Sun W, Xing B, Sun Y, et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Molecul Cellul Proteom. 2007;6:1798-808. (Pubitemid 350031681)
12. Kolkman A, Dirksen EH, Slijper M, et al. Double standards in quantitative proteomics: direct comparative assessment of difference in gel electrophoresis andmetabolic stable isotope labeling. MoleculCellul Proteom. 2005;4:255-66. (Pubitemid 40439769)
13. Zhou G, Li H, DeCamp D, et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific proteinmarkers. Molecul Cellul Proteom. 2002;1:117-24.
14. Huang HL, Stasyk T, Morandell S, et al. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis. 2006;27:1641-1650.
15. Griffin JL, Bollard ME. Metabonomics: its potential as a tool in toxicology for safety assessment and data integration. Curr Drug Metabol. 2004;5:389-398. (Pubitemid 39276603)
16. Nicholson JK, Lindon JC, Holmes E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-1189.
17. Nicholson JK, Connelly J, Lindon JC, et al. Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev Drug Disc. 2002;1:153-161. (Pubitemid 41646523)
18. Yu K, Sheng GP, Sheng JF, et al. A metabonomic investigation on the biochemical perturbation in liver failure patients caused by hepatitis B virus. J Proteome Res. 2007;6:2413-2419. (Pubitemid 47122338)
19. Griffin JL, Shockcor JP.Metabolic profiles of cancer cells. Nature Rev Cancer. 2004;4:551-561. (Pubitemid 38868624)
20. Ma YL, Peng JY, Liu WJ, et al. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Molecul Cellul Proteom. 2009;8:1878-1890.
21. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Laborat Sci. 2007;44:151-178.
22. Murray MJ, Lessey BA. Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis. Sem Reprod Endocrinol. 1999;17:275-290.
23. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
24. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452:571-579. (Pubitemid 351483371)
25. Faca VM, Song KS, Wang H, et al. A mouse to human search for plasma Proteome changes associated with pancreatic tumor development. Plos Med. 2008;5:953-967.
26. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 1996;14:2843-77.
27. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878. (Pubitemid 32230890)
28. Ma YL, Peng JY, Huang L, et al. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis. 2009;30:2591-2599.
29. Ma Y, Liu W, Peng J, et al. A pilot study of gas chromatograph/mass spectrometry-based serum metabolic profiling of colorectal cancer after operation. Mol Biol Rep. 2010;37:1403-1411.
30. Jonsson P, Johansson AI, Gullberg J, et al. High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. Anal Chem. 2005;77:5635-5642. (Pubitemid 41268639)
31. Hassan SS, Romero R, TarcaAL, et al. Signature pathways identified from gene expression profiles in the human uterine cervix before and after spontaneous term parturition. Am J Obstet Gynecol. 2007;197:250.e1-250.e7.
32. Dezso Z, Nikolsky Y, Sviridov E, et al. A comprehensive functional analysis of tissue specificity of human gene expression. Bmc Biol. 2008;6:49.
33. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nature Rev Canc. 2002;2:897-909. (Pubitemid 37328891)
34. Byrne JC, Downes MR, O'Donoghue N, et al. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res. 2009;8:942-957.
35. Li Z, Zhao X, Bai S, et al. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Molecul Cellul Proteom. 2008;7:1810-1823.
36. Hendrix MJ, Seftor EA, Seftor RE, et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nature Rev Cancer. 2007;7:246-255. (Pubitemid 46480969)
37. Lee NPY, Leung KW, Cheung N, et al. Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics. 2008;8:2136-2149. (Pubitemid 351775792)
38. Leung CL, Sun D, Zheng M, et al. Microtubule actin cross-linking factor (MACF): a hybrid of dystonin and dystrophin that can interact with the actin and microtubule cytoskeletons. J Cell Biol. 1999;147:1275-1286.
39. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810. (Pubitemid 39488658)
40. Wallingford JB, Habas R. The developmental biology of Dishevelled: an enigmatic protein governing cell fate and cell polarity. Development. 2005;132:4421-4436. (Pubitemid 41632222)
41. Chen HJ, Lin CM, Lin CS, et al. The role of microtubule actin cross-linking factor 1 (MACF1) in the Wnt signaling pathway. Genes Dev. 2006;20(14):1933-1945.
42. Habas R. Canonical Wnt signaling: an unexpected new player. Developmental Cell. 2006;11:138-139. (Pubitemid 44138505)
43. Sonnenberg A, Liem RK. Plakins in development and disease. Exp Cell Res. 2007;313:2189-2203. (Pubitemid 46842974)
44. Sjoblom T, Jones S,Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268-274. (Pubitemid 44571966)
45. Sakai T, Balasubramanian K, Maiti S, et al. Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. Am J Pathol. 2007;171:1659-1669.
46. Balasubramanian K,Maiti SN, Schroit AJ. Recruitment of beta-2-glycoprotein 1 to cell surfaces in extrinsic and intrinsic apoptosis. Apoptosis. 2005;10:439-446. (Pubitemid 40603496)
47. Cooke NE, McLeod JF, Wang XK, et al. Vitamin D binding protein: genomic structure, functional domains, and mRNA expression in tissues. J Steroid Biochem Mol Biol. 1991;40:787-793.
48. Kisker O, Onizuka S, Becker CM, et al.VitaminDbinding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia. 2003;5:32-40. (Pubitemid 36151056)
49. Denkert C, Budczies J,Weichert W, et al.Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer. 2008;7:72.
50. OkadaA, TakeharaH,Yoshida K, et al. Increased aspartate and glutamate levels in both gastric and colon cancer tissues.Tokushima J ExpMed. 1993;40:19-25.
51. Fu TF, Rife JP, Schirch V. The role of serine hydroxymethyltransferase isozymes in one-carbon metabolism in MCF-7 cells as determined by (13)C NMR. Arch Biochem Biophys. 2001;393:42-50. (Pubitemid 32808357)
52. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
53. Chan EC, Koh PK, Mal M, et al. Metabolic profiling of human colorectal cancer using high-resolutionmagic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res. 2009;8:352-361.
54. Nishihira T, Takagi T,Mori S. Leucine and manifestation of antitumor activity by valine-depleted amino acid imbalance. Nutrition. 1993;9:146-152. (Pubitemid 23131602)
55. Gribbestad IS, Sitter B, Lundgren S, et al. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res. 1999;19:1737-1746. (Pubitemid 29392730)
56. Denkert C, Budczies J, Kind T, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006;66:10795-10804. (Pubitemid 44876975)
57. Fang F, He X, Deng H, et al. Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis. Cancer Sci. 2007;98:1678-1682. (Pubitemid 47487900)
58. Dezso Z, Nikolsky Y, Nikolskaya T, et al. Identifying disease-specific genes based on their topological significance in protein networks. Bmc Syst Biol. 2009;3:36.
59. Bugrim A, Nikolskaya T, Nikolsky Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov Today. 2004;9:127-135. (Pubitemid 38198311)